BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The 2017 annual meeting of stockholders of the Company (the 2017
Annual Meeting) was held on June 14, 2017. At the 2017 Annual
Meeting, the holders of 6,736,339 shares of the Companys common
stock were represented in person or by proxy, thereby
constituting a quorum.
Set forth below are the final voting results for each of the
matters submitted to a vote of the stockholders of the Company at
the 2017 Annual Meeting.
Proposal 1. The stockholders of the Company
elected Dr. Mark Wegman, Toby Wegman and Jennifer Chao to the
Board of Directors, each to serve until the 2020 annual meeting
of stockholders or until such person resigns, is removed, or
otherwise leaves office. The votes were cast as follows:
| Director Name | For | Withheld |
| Dr. Mark Wegman | 3,392,873 | 2,466,556 |
| Toby Wegman | 3,620,551 | 2,338,878 |
| Jennifer Chao | 3,462,959 | 2,396,470 |
Proposal 2. The stockholders of the Company
approved, on an advisory basis, the Companys named executive
officer compensation as disclosed in the Companys proxy statement
filed with the Securities and Exchange Commission on April 28,
2017.
| For | Against | Abstain |
| 5,052,579 | 799,451 | 7,399 |
Proposal 3. The stockholders of the Company
approved, on an advisory basis, one-year intervals for the
frequency of future advisory votes on the compensation of the
Companys named executive officer.
| One-Year | Two-Year | Three-Year | Abstain |
| 4,216,114 | 67,039 | 616,063 | 960,213 |
Proposal 4. The stockholders of the Company
approved the ratification of the appointment of EisnerAmper LLP
as the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017. The votes were cast as
follows:
| For | Against | Abstain |
| 6,501,487 | 228,281 | 6,571 |
About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.